Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma by unknown
RESEARCH Open Access
Prognostic performance of pre-treatment
NLR and PLR in patients suffering from
osteosarcoma
Wen-Kai Xia1, Zhi-Li Liu2, Dong Shen2, Qing-Feng Lin2, Jun Su2 and Wei-Dong Mao2*
Abstract
Background: Inflammatory response markers have been proposed to predict the clinical outcomes in various
cancers. The aim of this study was to explore the influence of the neutrophil-to-lymphocyte ratio (NLR) and
platelet-to-lymphocyte ratio (PLR) on the prognosis of osteosarcoma.
Methods: Three hundred fifty-nine patients who underwent curative surgery for osteosarcoma were enrolled from
2005 to 2010. NLR and PLR were calculated from peripheral blood cell counts taken at pre-treatment. Optimal
cutoff values of NLR and PLR were determined on the basis of receiver operating characteristic curve analysis. A
predictive model was established to predict the clinical outcome for overall survival, and the predictive accuracy of
this model was determined by concordance index (c-index).
Results: Our results showed that advanced stage and metastasis at diagnosis were significantly associated with the
high NLR and PLR groups. NLR was an independent prognostic indicator for overall survival (HR = 1.80, 95 % CI =
1.35–2.41, P < 0.001) and progression-free survival (HR = 1.65, 95 % CI = 1.26–2.15, P < 0.001), except for PLR. The
nomogram could perform well in the prediction of overall survival in patients with osteosarcoma (c-index 0.829).
Conclusions: Our results suggest that both NLR and PLR can reflect clinical prognosis. NLR is more predictive of
overall survival and progression-free survival than PLR.
Keywords: Osteosarcoma, NLR, PLR, Prognosis
Background
Osteosarcoma is one of the most frequent malignant tu-
mors of the bone [1]. Two peaks of incidence appear in
osteosarcoma patients, such as children and early ado-
lescence aged 15 to 19 years [2]. Patients’ age is increas-
ing [3], which the number of patients over 40 years old
account for 13–30 % of osteosarcoma patients [4]. Due
to its rapid progression and poor prognosis, osteosar-
coma is a major death-causing disease [5]. Despite sub-
stantial progress achieved in the diagnosis and treatment
for osteosarcoma in the past decades, its clinical out-
come remains unsatisfactory due to local relapse or me-
tastasis after resection of primary osteosarcoma.
The poor prognosis of osteosarcoma partially results
from lack of a better biomarker to detect it at an early
tumor stage. The ability to predict the precise prognosis
of a patient is indispensible for selecting the appropriate
treatment plan and follow-up strategies. Although prog-
nostic indicators have the Enneking surgical criteria [6]
and alkaline phosphatase, heterogeneous clinical out-
comes are frequently observed within the same tumor
stage. Therefore, it is necessary for us to further under-
stand underlying mechanisms and find a useful bio-
marker of osteosarcoma to predict clinical outcome.
Recently, emerging evidence revealed that systemic in-
flammatory response has been reported to be an inde-
pendent prognostic biomarker in various types of tumors.
Published literatures have shown a significant link be-
tween inflammatory markers and poor survival in several
types of tumors, including thrombocytosis, leukocytosis,
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high neutrophil-to-lymphocyte ratio (NLR), or platelet-to-
lymphocyte ratio (PLR) [7–11]. However, the influence of
NLR and PLR on the prognosis of osteosarcoma patients
has been not reported. Herein, the purpose of this study
was to evaluate the influence of NLR and PLR on clinical




The Medical Ethics Committee of The Affiliated Jiangyin
Hospital, School of Medicine, Southeast University ap-
proved this study. Informed consent has been obtained
from each patient. Medical records of all newly diag-
nosed osteosarcoma patients between 2005 and 2010 in
The Affiliated Jiangyin Hospital, School of Medicine,
Southeast University were reviewed and retrospectively
analyzed in the present study. The diagnosis of osteosar-
coma was confirmed depended on histological evidence
and classified based on the Enneking surgical criteria [6].
The inclusion criteria were as follows. (1) All patients
with osteosarcoma underwent a corresponding appropri-
ate treatment according to standard therapeutic strat-
egies. (2) Inflammatory markers were obtained prior to
anticancer treatment, such as surgery, blood transfusion,
chemotherapy, and radiotherapy. (3) No hematology dis-
ease, infection, and hyperpyrexia. Finally, 359 patients
were enrolled in the present study. Clinical features of
eligible patients were collected including age, sex, tumor
location, pathological fracture, tumor size, alkaline phos-
phatase (ALP), clinical stage, metastasis at diagnosis, and
post-operative chemotherapy.
Blood sample analysis
Blood samples were obtained before treatment for the
measurement of the white cell, neutrophil, lymphocyte,
and platelet counts.
Definition and optimal cutoff values of NLR and PLR
NLR was defined as the neutrophil counts divided by
the lymphocyte counts. PLR was defined as the platelet
counts divided by the lymphocyte counts. Using overall
survival and progression-free survival, respectively, as
end points, optimal cutoff values of NLR and PLR were
obtained when the Youden index was maximal. Subse-
quently, patients with a NLR or PLR greater than the
corresponding cutoff values were defined as high NLR
or PLR (HNLR or HPLR), and others were defined as
low NLR or PLR (LNLR or LPLR).
Patient follow-up
Each patient was followed up regularly until death or
December 2014 at post-operation (every 3 months for the
first 2 years and then every 6 months up to the 5th year).
Physical examination, laboratory tests, and imageological
diagnosis were performed at every visit. The follow-up
period varied from 3 months to 5 years, with a median of
40 months. Overall survival (OS) was calculated from
treatment to death. The date of last follow-up was used
for dropout patients. Progression-free survival (PFS) was
collected from treatment to disease progression or relapse
or until the date of the last follow-up.
Statistical analysis
To evaluate the sensitivity and specificity for the 5-year OS
and PFS, the receiver operating characteristic (ROC) curve
was applied, and the largest Youden’s index was estimated
to determine the optimal NLR and PLR cutoff values. Com-
parison of categorical variables was conducted using a chi-
square test. Comparison of continuous variables was per-
formed using Mann-Whitney U or Kruskal-Wallis test. Sur-
vival curves were plotted by the Kaplan-Meier method, and
the significance was assessed by the log-rank test. The sig-
nificant predictors for OS and PFS determined by univari-
ate analysis were evaluated by multivariate analysis using
Cox’s proportional hazards model. Nomogram for OS was
constructed by R 3.0.3 software (Institute for Statistics and
Mathematics, Austria), and Harrell’s concordance index (c-
index) was used to evaluate the predictive accuracy. All re-
sults analyses were performed by SPSS 20.0 software (IBM,
USA). P < 0.05 was considered statistically significant.
Results
Clinicopathological characteristics
Of 359 patients with osteosarcoma, 258 (71.87 %) were
male, and the median age was 50 years (range 19–
69 years; Table 1); 62 (17.27 %) patients with patho-
logical fracture and 132 (36.77 %) patients with initial
metastasis were recorded from newly diagnosed patients.
According to Enneking surgical staging criteria, the
number of stages I–II and III was 161 (44.85 %) and 198
(55.15 %), respectively. Pathological results suggested
that 290 (80.78 %) patients’ osteosarcomas were located
in the tibia or femur, and tumor size was more than
8 cm in 158 (44.01 %) patients with osteosarcoma. Dur-
ing the follow-up period, 187 (50.09 %) patients had ex-
perienced chemotherapy. Among all enrolled patients,
211 (58.77 %) patients died from cancer-related disease;
249 (69.40 %) patients were detected as local recurrence
or metastasis. The median values of the pre-operative
white blood cells, neutrophil, lymphocyte, and platelet
counts were 6.20 × 109/L, 4.16 × 109/L, 1.24 × 109/L, and
183 × 109/L, respectively. The median values of NLR and
PLR were 3.19 and 142, respectively.
The optimal cutoff values for NLR and PLR
When OS was employed as an end point for NLR and
PLR, the areas under the curve (AUC) for NLR, PLR,
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and ALP were 0.705 (P < 0.001), 0.606 (P = 0.001), and
0.529 (P = 0.357), respectively (Fig. 1a). Subsequently,
ALP was excluded due to its small AUC (P > 0.05). The
optimal cutoff values were 3.43 for NLR (sensitivity,
59.7 %; specificity, 74.3 %) and 122 for PLR (sensitivity,
70.6 %; specificity, 50.0 %). Similarly, using PFS as an
end point for them, the cutoff values of NLR and PLR
were 3.67 (sensitivity, 49.8 %; specificity, 80.0 %) and 122
(sensitivity, 44.6 %; specificity, 66.4 %), respectively
(Fig. 1b). All patients were divided into two groups with
the high groups that are greater than or equal to the cut-
off values (HNLR and HPLR) and the low groups less
than the cutoff values (LNLR and LPLR) on the basis of
the optimal cutoff values.
Table 1 Association of the patients’ clinical parameters with NLR and PLR
Clinical parameters Total NLR P PLR P
Low NLR High NLR Low PLR High PLR
n = 359 (%) n = 195 (%) n = 164 (%) n = 136 (%) n = 223 (%)
Age (year)a 48.7 ± 12.4 48.5 ± 11.5 49.0 ± 13.4 0.536 46.4 ± 12.3 50.2 ± 12.3 0.006
Sex
Male 258 (71.87 %) 137 (70.26 %) 121 (73.78 %) 0.459 92 (67.65 %) 166 (74.44 %) 0.165
Female 101 (28.13 %) 58 (29.74 %) 43 (26.22 %) 44 (32.35 %) 57 (25.56 %)
Tumor location
Tibia/femur 290 (80.78 %) 156 (80.00 %) 134 (81.71 %) 0.683 104 (76.47 %) 186 (83.41 %) 0.106
Elsewhere 69 (19.22 %) 39 (20.00 %) 30 (18.29 %) 32 (23.53 %) 37 (16.59 %)
Pathological fracture
Yes 62 (17.27 %) 37 (18.97 %) 25 (15.24 %) 0.352 25 (18.38 %) 37 (16.59 %) 0.663
No 297 (82.73 %) 158 (81.03 %) 139 (84.76 %) 111 (81.62 %) 186 (83.41 %)
Tumor size
<8 cm 201 (55.99 %) 110 (56.41 %) 91 (55.49 %) 0.861 76 (55.88 %) 125 (56.05 %) 0.975
≥8 cm 158 (44.01 %) 85 (43.59 %) 73 (44.51 %) 60 (44.11 %) 98 (43.95 %)
ALP
Elevated 104 (28.97 %) 48 (24.62 %) 56 (34.15 %) 0.047 35 (25.74 %) 69 (30.94 %) 0.291
Normal 255 (71.03 %) 147 (75.38 %) 108 (65.85 %) 101 (74.26) 154 (69.06 %)
Clinical stageb
I–II 161 (44.85 %) 111 (56.92 %) 50 (30.49 %) 0.000 73 (53.68 %) 88 (39.46 %) 0.009
III 198 (55.15 %) 84 (43.08 %) 114 (69.51 %) 63 (46.32 %) 135 (60.54 %)
Metastasis at diagnosis
Present 132 (36.77 %) 41 (21.03 %) 91 (55.49 %) 0.000 33 (24.26 %) 99 (44.39 %) 0.000
Absent 227 (63.23 %) 154 (78.97 %) 73 (44.51 %) 103 (75.74 %) 124 (55.61 %)
Post-chemotherapy
Yes 187 (50.09 %) 95 (48.72 %) 92 (56.10 %) 0.163 67 (49.26 %) 120 (53.81 %) 0.403
No 172 (47.91 %) 100 (51.28 %) 72 (43.90 %) 69 (50.74 %) 103 (46.19 %)
WBC counts (*109/L)c 6.20 (1.90–26.68) 5.04 (1.90–13.00) 8.01 (3.10–26.68) 0.000 5.71 (1.90–24.02) 6.64 (2.20–26.68) 0.027
Neutrophil counts (*109/L)c 4.16 (0.84–26.07) 2.91 (0.84–7.40) 6.50 (2.42–26.07) 0.000 3.47 (0.84–21.93) 4.88 (1.10–26.07) 0.000
Lymphocyte counts (*109/L)c 1.24 (0.09–4.84) 1.59 (0.61–4.84) 0.91 (0.09–4.46) 0.000 1.62 (0.54–4.84) 1.06 (0.09–2.62) 0.000
Platelet counts (*109/L)c 183 (18–516) 183 (26–516) 175 (18–490) 0.890 141 (26–292) 225 (18–516) 0.000
NLR 3.19 (0.79–74.49)
PLR 142 (5.4–3111)
ALP alkaline phosphatase, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
aMean ± SD
bClinical stage according to Enneking surgical stage
cMedian (range)
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The associations of NLR and PLR with clinicopathological
features
To investigate the associations of NLR and PLR with
clinicopathologic features of osteosarcoma patients,
comparisons between the high and low groups for NLR
and PLR was carried out (Table 1). Our results indicated
that advanced stage and metastasis at diagnosis were sig-
nificantly associated with the high NLR and PLR groups.
Elevated ALP and older age were closely associated with
the high NLR and PLR, respectively.
Prognostic factors for OS and PFS
The 5-year OS rates of the HNLR and HPLR groups
were significantly lower than those of the LNLR and
LPLR groups (P < 0.001; Fig. 2a, b). Similarly, osteosar-
coma patients with HNLR and HPLR had poorer PFS
than those with LNLR and LPLR (P ≤ 0.001; Fig. 3a, b).
Subsequently, the multivariate analyses of OS and PFS
were performed including age, sex, and clinical variables
with univariate log-rank P < 0.05: clinical stage, metasta-
sis at diagnosis, NLR, and PLR. HNLR, clinical stage,
and metastasis emerged as markers for shorter OS and
PFS (Table 2). However, HPLR was not an independent
indicator for both OS and PFS.
Prognostic nomogram for OS
To further predict the survival of osteosarcoma patients
after surgical resection, a predictive model was con-
structed by Cox regression model analysis using all the
significant independent risk factors for OS (Fig. 4). It
can predict the probability of death of osteosarcoma
within 3 or 5 years after treatment, assuming the patient
does not die of another cause first. The c-index for OS
prediction was 0.829.
Discussion
We investigated two factors which have reflected a sys-
temic inflammatory response. The pre-treatments HNLR
and HPLR in the peripheral blood of osteosarcoma pa-
tients were significantly associated with tumor progres-
sion and poor prognosis at post-operation. Despite
substantial progress in the understanding of the associ-
ation between inflammatory biomarkers and prognosis
of various cancers [11–13], the influence of inflamma-
tory markers on the prognosis of osteosarcoma patients
remains confused. Herein, this study was the first at-
tempt to evaluate the prognosis of patients with osteo-
sarcoma based on inflammatory biomarkers in the
peripheral blood and to construct a predictive model to
improve the predictive accuracy. Because the peripheral
blood count test is routinely performed without the need
for additional effort in all patients with cancer, it is a
simple, inexpensive, and reproducible parameter of the in-
flammatory response as well as an indicator of prognosis.
Interestingly, only NLR could be considered as an inde-
pendent indicator for OS and PFS in multivariate analysis.
Rudolf Virchow first reported that “lymphoreticular in-
filtrate” reflected the origin of tumor at the sites of chronic
Fig. 1 ROC curves for NLR, PLR, and ALP. a Overall survival (cutoff value of NLR, 3.43; PLR, 122). b Progression-free survival (cutoff value of NLR,
3.67; PLR, 122)
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inflammation [14]. Over the past decades, the emerging
evidence verified Virchow’s hypothesis revealing the influ-
ence of inflammatory microenvironment on tumor. The
inflammatory reaction, which is implicated in repair of tis-
sue damage due to tumors, is an indispensible factor in
the tumor cell microenvironment [15, 16]. Thus, inflam-
matory cells are involved in cell proliferation, invasion,
migration, angiogenesis, and metastasis. Meanwhile, tu-
mors can result from inflammatory sites, possibly through
the recruitment of inflammatory cells, chemokines, and
cytokines. Therefore, the adaptive immune system is con-
verted, and this inflammatory response reactivates tumor
development and progression. The inflammatory response
could result in neutrophilia, leukocytosis, thrombocytosis,
Fig. 3 Kaplan-Meier curves for progression-free survival probability according to NLR and PLR levels (a, b)
Fig. 2 Kaplan-Meier curves for overall survival probability according to NLR and PLR levels (a, b)
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and lymphocytopenia [17]. The platelets may increase
angiogenesis and release growth factors to participate in
the inflammatory reaction [18]. The lymphocyte response
plays a critical role in the suppression of tumor progression
[19]. The possible mechanisms underlying neutrophilia in
progression and metastasis have release of reactive oxygen
species or nitric oxide and remodeling of the extracellular
matrix [20]. Hence, more deep understanding of the links
between inflammation and tumor contributes to the treat-
ment and prevention of tumor. Several markers have been
reported to reflect the association of inflammation and
tumor, such as interferon-gamma/interleukin-4 ratio [21]
and inflammation-based prognostic score based on CRP
and albumin levels [22]. The systemic inflammatory
markers (NLR and PLR) may be also regarded as potential
prognostic factors for various types of tumors. Azap et al.
Table 2 Univariate and multivariate analyses of clinical parameters for the prediction of overall and progression-free survival
Clinical
parameters
Overall survival Progression-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR P Adjusted HR (95 % CI) P HR P Adjusted HR (95 % CI) P
Age (year)
≦50 1.00 1.00 1.00 1.00
>50 1.09 0.540 1.08 (0.82–1.41) 0.598 1.10 0.436 1.08 (0.84–1.39) 0.543
Sex
Male 1.00 1.00 1.00 1.00
Female 0.93 0.634 1.06 (0.78–1.44) 0.695 0.97 0.844 1.02 (0.77–1.35) 0.889
Tumor location
Tibia/femur 1.00 1.00
Elsewhere 0.99 0.963 0.89 0.378
Pathological fracture
Yes 1.00 1.00
No 0.81 0.275 0.98 0.887
Tumor size 1.00
<8 cm 1.00 1.04 0.754
≥8 cm 1.09 0.524
ALP
Normal 1.00 1.00
Elevated 1.28 0.094 1.30 0.055
Clinical stagea
I–II 1.00 1.00 1.00 1.00
III 4.63 0.000 2.49 (1.66–3.72) 0.000 3.32 0.000 2.24 (1.59–3.15) 0.000
Metastasis at diagnosis
Absent 1.00 1.00 1.00 1.00
Present 5.09 0.000 2.43 (1.69–3.49) 0.000 3.42 0.000 1.72 (1.23–2.40) 0.002
Post-chemotherapy
Yes 1.00 1.00
No 1.02 0.865 1.05 0.687
NLR
Low NLR 1.00 1.00 1.00 1.00
High NLR 2.65 0.000 1.80 (1.35–2.41) 0.000 2.24 0.000 1.65 (1.26–2.15) 0.000
PLR
Low PLR 1.00 1.00 1.00 1.00
High PLR 1.84 0.000 1.27 (0.93–1.73) 0.136 1.57 0.001 1.17 (0.88–1.55) 0.273
ALP alkaline phosphatase, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, HR hazard ratio, CI confidence interval
aClinical stage according to Enneking surgical stage
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used pre-treatment NLR and PLR as prognostic indicators
of long-term mortality in patients with breast cancer [23].
Deng et al. reported that pre-operative NLR was a superior
independent prognostic factor for cancer-specific survival
in surgical patients with gastric cancer [11]. He et al. com-
pared NLR to PLR as an adverse prognostic factor in meta-
static colorectal cancer and suggested that NLR was
superior to PLR [24].
Little evidence has shown that NLR and PLR are associ-
ated with prognosis in osteosarcoma. Our study was the
first attempt to evaluate the impact of NLR and PLR on
prognosis of 359 osteosarcoma patients and establish a
predictive model to improve the predictive accuracy for 3-
year and 5-year overall survival. Similar to other results in
various cancers, pre-treatment NLR and PLR were signifi-
cantly associated with poor prognosis. Interestingly, only
NLR could be considered as an independent prognostic
factor for both OS and PFS in patients with osteosarcoma.
Our constructed nomogram performed well in the predic-
tion of overall survival (c-index 0.829). These data sup-
ported that the nomogram could better predict prognosis
in osteosarcoma patients at pre-treatment.
Some limitations of our study should be acknowl-
edged. Firstly, the study was a retrospective design,
with a small population size of 359 patients, which
resulted in no significant correlation between chemo-
therapy and clinical prognosis. Secondly, the periph-
eral blood findings were not compared with findings
of peritumoral inflammation in the primary tumor tis-
sue. Nevertheless, the data in the peripheral blood
provided a novel horizon to understand the roles of
NLR and PLR in the development and progression of
osteosarcoma. Finally, there were some heterogeneities
in the treatment of osteosarcoma patients, which re-
sulted in different clinical prognosis. Hence, further
studies are necessary to illuminate the relationship
between inflammatory biomarkers and prognosis in
patients with osteosarcoma.
Conclusions
The pre-treatment NLR and PLR are associated with
survival in patients with osteosarcoma. NLR is a better
predictor of OS and PFS than PLR. Integrate NLR and
PLR and the prognostic nomogram may be used to
evaluate clinical prognosis and offer optimal therapeutic
strategy. In the future, a well-designed study of NLR,
PLR, and other promising indicators should be per-
formed to identify the underlying mechanism.
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